Oral and injectable formulations of tetracycline compounds
View Patent ↗Injectable and oral formulations of a tetracycline compound are described. In one embodiment, the invention pertains to an oral formulation of a 9-aminomethyl tetracycline compound, or a salt thereof, in tablet form or capsule. The formulations may be used, for example, to treat infections.
1. An oral formulation in tablet form, comprising about 19% to about 22% weight percent of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, a diluent, a stabilizer, a glidant, a lubricant, and a disintegrant, wherein the oral formulation is compressed using roller compaction.
2. The oral formulation of claim 1 , comprising 90-250 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof.
3. The oral formulation of claim 1 , wherein the oral formulation comprises about 20% weight percent of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline.
4. The oral formulation of claim 1 , wherein the oral formulation comprises about 50% to about 90% weight percent of a diluent.
5. The oral formulation of claim 4 , wherein the diluent comprises lactose and microcrystalline cellulose.
6. The oral formulation of claim 5 , wherein the oral formulation comprises about 10% to about 30% weight percent of lactose.
7. The oral formulation of claim 5 , wherein the oral formulation comprises about 30% to about 50% weight percent of microcrystalline cellulose.
8. The oral formulation of claim 1 , wherein the stabilizer is sodium bisulfite.
9. The oral formulation of claim 8 , wherein the oral formulation comprises about 0.001% to about 0.5% weight percent of sodium bisulfite.
10. The oral formulation of claim 1 , wherein the glidant is colloidal silicon dioxide.
11. The oral formulation of claim 10 , wherein the oral formulation comprises about 0.1% to about 1.5% weight percent of colloidal silicon dioxide.
12. The oral formulation of claim 1 , wherein the lubricant is sodium stearyl fumarate.
13. The oral formulation of claim 12 , wherein the oral formulation comprises about 2% to about 10% weight percent of sodium stearyl fumarate.
14. The oral formulation of claim 1 , wherein the disintegrant is crospovidone.
15. The oral formulation of claim 2 , wherein the oral formulation comprises:
about 140 mg to about 180 mg of lactose;
about 290 mg to about 315 mg of microcrystalline cellulose;
about 0.1 mg to about 2 mg of sodium bisulfite;
about 1.0 mg to about 12 mg of silicon dioxide; and
about 10 mg to about 110 mg of sodium stearyl fumarate.
16. The oral formulation of claim 1 , wherein the oral formulation comprises:
about 50-90% weight percent of a diluent;
about 0.01-0.5% weight percent of a stabilizer;
about 0.2-2.0% weight percent of a glidant;
about 3-10% weight percent of a lubricant;
about 0-2.0% weight percent of an antiadherent; and
about 1-6% weight percent of a coating component.
17. The oral formulation of claim 1 , wherein the oral formulation comprises:
about 10 to about 30% weight percent of lactose;
about 30% to about 50% weight percent of microcrystalline cellulose;
about 0.001% to about 0.5% weight percent of sodium bisulfite;
about 0.1% to about 1.5% weight percent of colloidal silicon dioxide; and
about 2% to about 10% weight percent of sodium stearyl fumarate.
18. The oral formulation of claim 2 , wherein the oral formulation comprises:
about 50 mg to about 150 mg of lactose;
about 0.5 mg to about 10.0 mg of colloidal silicon dioxide; and
about 5 mg to about 80 mg of sodium stearyl fumarate.
19. An oral formulation in tablet form, comprising about 19% to about 22% weight percent of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline tosylate salt, lactose, microcrystalline cellulose, sodium bisulfite, colloidal silicon dioxide, sodium stearyl fumarate and crosspovidone, wherein the oral formulation is compressed using roller compaction.
20. The oral formulation of claim 19 , comprising 90-250 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline tosylate salt, lactose, microcrystalline cellulose, sodium bisulfite, colloidal silicon dioxide, sodium stearyl fumarate and crosspovidone.
21. The oral formulation of claim 1 , wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof is 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline tosylate salt.
22. The oral formulation of claim 19 , wherein the oral formulation comprises about 20% weight percent of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline.